Fierce Biotech1 min read
savePfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
Pfizer has decided to join the in vivo CAR-T race, penning a $2.6 billion deal for three preclinical candidates from China’s Starna Therapeutics.
comments(0)
5-min edit window · permanent after that